Guggenheim analyst Vamil Divan downgraded Chinook Therapeutics (KDNY) to Neutral from Buy with a price target of $40, up from $35, after the company agreed to be acquired by Novartis (NVS) for $40 per share in cash plus an additional $4 per share that may be payable through a contingent value right, or CVR. The deal reinforces the firm’s view that Chinook is “a best-in-class story in the renal/IgAN space” and also supports the firm’s expectation for an increase in M&A and business development activity in the renal space given continued progress by Chinook and others in developing drugs for IgA nephropathy, or IgAN, and other difficult-to-treat and underserved conditions, the analyst tells investors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KDNY:
- Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
- Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
- KDNY Upcoming Earnings Report: What to Expect?
- Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
